
Rhythm Biosciences is a cancer diagnostics technology company whose ColoSTAT is a blood-based colorectal cancer test for symptomatic patients.
rhythmbio.comCrawled Nov 17, 2026
Sally earned a BSc Honours degree in biochemistry from Leeds University in 1998 and joined the NHS Clinical Scientist training programme in 2000. She became a Fellow of the Royal College of Pathologists in 2008 and later worked as a Consultant Clinical Biochemist at Barts Health NHS Trust before moving to her current role in Guildford, where she leads a team of research scientists.
Board of Directors for ASX Listed Company Rhythm Biosciences
The page describes expertise in clinical and molecular diagnostics, surgery, orthopaedics, and cell and gene therapy, along with international business leadership in sales, R&D, and operations.
Rhythm Biosciences has partnered with a US manufacturer to advance production of its colorectal cancer blood test, ColoSTAT. The deal supports the company’s push toward commercializing the diagnostic tool, which detects cancer through blood analysis. This manufacturing agreement marks a critical step in preparing ColoSTAT for broader market availability.
Rhythm Biosciences publishes peer-reviewed validation of its ColoSTAT blood test in the *Journal for Gastrointestinal Cancer*. The study confirms the test’s clinical performance in detecting colorectal cancer. CEO David Atkins and clinical director Dr. Andy Feber discuss the findings, highlighting potential advancements in early cancer diagnosis.
Rhythm Biosciences partners with datma to integrate datma.FED into its cancer risk prediction tools. The collaboration aims to enhance genomic diagnostic capabilities by leveraging datma’s platform for precision medicine applications. Both companies focus on advancing early detection and personalized treatment strategies in oncology.
Rhythm’s ColoSTAT test demonstrates consistent bowel cancer detection performance regardless of age or gender. The tool supports earlier identification of bowel cancer by maintaining accuracy across diverse patient demographics. Clinical validation highlights its potential to improve screening equity and outcomes.
Australian Securities Exchange (ASX)-listed companies are developing and deploying technologies to improve breast cancer detection, treatment, and patient outcomes. These firms contribute to innovations in diagnostics, therapeutics, and supportive care, addressing critical gaps in early intervention and personalized medicine. Collaborations with research institutions and global partners further accelerate progress in the field.